Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

122 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
[Place of molecular imaging in the management of prostate cancer].
Rousseau C, Le Thiec M, Maucherat B, Frindel M, Fleury V. Rousseau C, et al. Among authors: fleury v. Cancer Radiother. 2021 Oct;25(6-7):663-666. doi: 10.1016/j.canrad.2021.07.032. Epub 2021 Aug 14. Cancer Radiother. 2021. PMID: 34404605 Review. French.
Initial Clinical Results of a Novel Immuno-PET Theranostic Probe in Human Epidermal Growth Factor Receptor 2-Negative Breast Cancer.
Rousseau C, Goldenberg DM, Colombié M, Sébille JC, Meingan P, Ferrer L, Baumgartner P, Cerato E, Masson D, Campone M, Rauscher A, Fleury V, Labbe C, Chauvet AF, Fresnel JS, Toquet C, Barbet J, Sharkey RM, Campion L, Kraeber-Bodéré F. Rousseau C, et al. Among authors: fleury v. J Nucl Med. 2020 Aug;61(8):1205-1211. doi: 10.2967/jnumed.119.236000. Epub 2020 Mar 13. J Nucl Med. 2020. PMID: 32169921 Free PMC article. Clinical Trial.
Head-to-Head Comparison of 18F-DOPA PET/CT and 68Ga-DOTANOC PET/CT in Patients With Midgut Neuroendocrine Tumors.
Ansquer C, Touchefeu Y, Faivre-Chauvet A, Leux C, Le Bras M, Régenet N, Fleury V, Maucherat B, Senellart H, Guyetant S, Carlier T, Scotet-Cérato E, Rauscher A, Frampas E, Kraeber-Bodéré F. Ansquer C, et al. Among authors: fleury v. Clin Nucl Med. 2021 Mar 1;46(3):181-186. doi: 10.1097/RLU.0000000000003450. Clin Nucl Med. 2021. PMID: 33315677
Is Glucagon Administration Compatible With FDG PET/MRI?
Maucherat B, Movassaghi R, Fleury V, Le Thiec M, Geffroy D, Labbe-Devilliers C, Rousseau C. Maucherat B, et al. Among authors: fleury v. Clin Nucl Med. 2022 Aug 1;47(8):730-731. doi: 10.1097/RLU.0000000000004225. Epub 2022 Apr 15. Clin Nucl Med. 2022. PMID: 35426850
68Ga-PSMA-11 PET-CT study in prostate cancer patients with biochemical recurrence and non-contributive 18F-Choline PET-CT: Impact on therapeutic decision-making and biomarker changes.
Barbaud M, Frindel M, Ferrer L, Le Thiec M, Rusu D, Rauscher A, Maucherat B, Baumgartner P, Fleury V, Colombié M, Thierry-Morel A, Kraeber-Bodéré F, Campion L, Rousseau C. Barbaud M, et al. Among authors: fleury v. Prostate. 2019 Apr;79(5):454-461. doi: 10.1002/pros.23751. Epub 2018 Dec 14. Prostate. 2019. PMID: 30549066
Preliminary results of a 68 Ga-PSMA PET/CT prospective study in prostate cancer patients with occult recurrence: Diagnostic performance and impact on therapeutic decision-making.
Rousseau C, Le Thiec M, Ferrer L, Rusu D, Rauscher A, Maucherat B, Frindel M, Baumgartner P, Fleury V, Denis A, Morel A, Varmenot N, Debeaupuis E, Campion L, Kraeber-Bodéré F. Rousseau C, et al. Among authors: fleury v. Prostate. 2019 Sep;79(13):1514-1522. doi: 10.1002/pros.23869. Epub 2019 Aug 17. Prostate. 2019. PMID: 31421657 Clinical Trial.
122 results